English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Therapeutics targeting epigenetic regulators (1-3), immune modulators (4-6) and receptor tyrosine kinases (7-9) have emerged as promising drugs for cancer patients who are refractory to conventional chemotherapy, radiotherapy or surgery ( Figure 1 ). These cutting-edge therapeutics, together with next-generation sequencing (NGS) technologies that produce bulk genomics-related data as commodities of clinical medicine, have led to a gradual shift toward personalized or precision medicine.

journal of thoracic disease

Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine